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Introduction
W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide) and W-15
(4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide) were originally identified in
the patent literature as analogs of  the potent opioid agonist fentanyl (N-(1-(2-phenylethyl)-4-piper-
idinyl)-N-phenylpropanamide) (Figure 1) (1). Given the fact that W-18 and W-15 differ in key respects
chemically from fentanyl (Figure 1), it could be predicted that they might lack appreciable opioid receptor
agonist actions. The presence of  an aryl sulfonamide group renders the piperidine nitrogen atom nonba-
sic. A basic tertiary amine is commonly seen in most opioid templates. It could thereby be predicted that
both W-15 and W-18 might lack appreciable opioid receptor agonist activity. In the original description,
W-18 and W-15 (along with several other analogs) were described to be extraordinarily potent at inhibiting
phenylquinone-induced writhing — a mouse model useful for assessing potential analgesic actions for a
wide variety of  drugs, such as aspirin, antihistamines, opioids, antidepressants, sympathomimetics, ace-
tylcholinesterase inhibitors, and psychotomimetic opioids, such as cyclazocine (2). Thus, the inhibition
of  phenylquinone-induced writhing is a relatively nonspecific test for drugs with potential analgesic and
other activities. In the original report, there was no evidence that the activity in this model by either W-18
or W-15 was antagonized by the prototypical opioid antagonist naloxone, although the related compound
W-20 (1-cyclopropylmethylpiperidylidene-2-(4-chlorophenyl)sulfonamide) was reported to have modest
naloxone-reversible activity.
W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide) and W-15 
(4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide) represent two emerging 
drugs of abuse chemically related to the potent opioid agonist fentanyl (N-(1-(2-phenylethyl)-4-
piperidinyl)-N-phenylpropanamide). Here, we describe the comprehensive pharmacological profiles 
of W-18 and W-15, as examination of their structural features predicted that they might lack opioid 
activity. We found W-18 and W-15 to be without detectible activity at μ, δ, κ, and nociception opioid 
receptors in a variety of assays. We also tested W-18 and W-15 for activity as allosteric modulators 
at opioid receptors and found them devoid of significant positive or negative allosteric modulatory 
activity. Comprehensive profiling at essentially all the druggable GPCRs in the human genome using 
the PRESTO-Tango platform revealed no significant activity. Weak activity at the sigma receptors 
and the peripheral benzodiazepine receptor was found for W-18 (Ki = 271 nM). W-18 showed no 
activity in either the radiant heat tail-flick or the writhing assays and also did not induce classical 
opioid behaviors. W-18 is extensively metabolized, but its metabolites also lack opioid activity. 
Thus, although W-18 and W-15 have been suggested to be potent opioid agonists, our results reveal 
no significant activity at these or other known targets for psychoactive drugs.
Recently, W-18 (3–7) and perhaps W-15 have emerged as potential drugs of  abuse; W-18 is sched-
uled as a controlled substance in Canada (8) and is being considered for inclusion in Schedule 1 con-
trol in the US. To our knowledge, there are no other published reports on the pharmacology of  W-18 
or W-15. Accordingly, we here report a comprehensive evaluation of  the in vitro molecular pharma-
cology of  W-18 and W-15.
Results
Radioligand-binding assays reveal no activity of  W-18 at human, cloned opioid receptors. In our initial studies, 
we evaluated the ability of  W-15 and W-18 to interact with 3 canonical opioid receptors via radioli-
gand-binding studies performed as previously described using cloned, human κ (9, 10), μ (11), and δ 
opioid receptors (KOR, MOR, and DOR, respectively) (12, 13). No significant inhibition of  radioli-
gand binding was measured up to concentrations as high as 10,000 nM (Table 1). These studies were 
followed by investigation of  effects against the murine MOR, KOR, and DOR, with similar results. No 
inhibition of  binding with concentrations as high as 1 μM were observed. W-15 and/or W-18 inhibited 
radioligand binding at several nonopioid receptors with low affinities, including the 5-HT2A, 5-HT2B, 
5-HT2C, and 5-HT6 serotonin receptors; benzodiazepine receptors (BZP and PBR) (Table 1); and other
miscellaneous targets (Table 2).
Functional assays reveal no agonist, antagonist, or allosteric modulator activity of  W-18 or W-15 at human 
cloned opioid receptors. We next evaluated W-18 and W-15 for agonist and antagonist activity at cloned 
human opioid receptors in both Gi-dependent inhibition of  cAMP production and G protein–inde-
pendent arrestin translocation assays (Figures 2 and 3). No significant agonist or antagonist activity 
was measured up to doses as high as 10,000 nM, although nonspecific agonist effects were evident at 
high concentrations in these assays (Figure 2, A–D). We also evaluated the potential of  W-18 to be 
an allosteric modulator of  opioid receptors and found only weak and potentially nonspecific negative 
allosteric modulator actions in either Gi-cAMP or arrestin signaling (Figures 4 and 5).
Functional assays reveal antagonist activity at human 5-HT receptors. Since W-15 and W-18 displayed 
binding activities at 5-HT2 and 5-HT6 receptors, we examined their functional activity at 5-HT2A, 
5-HT2B, and 5-HT2C receptors for calcium mobilization and at 5-HT6 receptors for arrestin signaling.
W-15 and W-18 showed no agonist activity and modest antagonist activity at 5-HT2 receptors (Figure
6). Schild analysis with W-15 indicated competitive antagonism against 5-HT at 5-HT2 receptors, as
shown by the parallel shifts of  the agonist dose-response curves (Figure 7). At 5-HT6 receptors, W-15
and W-18 displayed no agonist activity (Figure 8). W-15 and W-18 also displayed weak binding at
Figure 1. Structure of fentanyl, W-15, and W-18. Shown are the chemical structures of fentanyl (left), W-15 (center), and W-18 (right). The structural 
similarities between fentanyl and W-15/W-18 are shown in red. The presence of aryl sulfonamide group (in blue) in both W-15/W-18 makes the piperidine 
nitrogen not charged at physiological pH compared with the fentanyl piperidine nitrogen.
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Results represent mean percentage of inhibition at 10 μM. Values are averages from triplicate or quadruplicate sets. BZP, 
brain benzodiazepine binding site (rat); PBR, peripheral benzodiazepine receptors; ND, not determined.
A1-adenosine, α2A-adrenergic, and CB2 cannabinoid receptors; we therefore examined the nature of
their activity at these receptors. Our results (Figure 8) indicated that the drugs had no agonist activity 
at any of  these examined receptors.
Screening of  W-18 and W-15 against the druggable GPCR-ome revealed no significant agonist activity at any 
human druggable GPCR. We next screened W-18 and W-15 against the druggable human GPCR-ome 
using our recently developed PRESTO-Tango resource (14). Although no significant agonist activity 
was reproducibly found, we did note that concentrations of  W-18 higher than 1 μM tended to cause a 
decrease in the overall baseline activity for nearly every target, consistent with a toxic activity at HEK 
cells with prolonged incubation (Figure 9).
We examined the metabolism of  W-18. W-18 was extensively metabolized by both human and 
mouse liver microsomes (Supplemental Figures 1–3), resulting in multiple monohydroxylated and 
dihydroxylated metabolites as well as a dealkylated and an amino metabolite from reduction of  the 
nitro group. To determine if  W-18 was a prodrug, releasing an active compound through metabolism, 
we incubated W-18 with liver microsomes, extracted the remaining W-18 and its metabolites, and 
tested the mixture in opioid receptor–binding assays at a concentration corresponding to 1 μM W-18 
prior to the microsomal incubation. The mixture of  W-18 and metabolites failed to significantly inhibit 
binding to murine MOR, DOR, or KOR expressed in Chinese hamster ovary (CHO) cells.
In silico studies. We also used the similarity ensemble approach to determine if  any molecular targets 
might be predicted with high expectancies to have activity for W-18. No target(s) emerged with high confi-
dence, although weak predictions (E = 4.67 e–1) suggested activity were for H3-histamine for W-18, which 
was not confirmed experimentally (Table 1).
In vivo evaluation. In the initial patent report, W-18 was active in the writhing assay, with a potency 
many times that of  morphine. When administered in mice at doses as high as 1 mg/kg, s.c., W-18 
failed to demonstrate any activity in either the radiant heat tail-flick assay or the writhing assay (Figure 
10 and Table 3). Treated mice failed to display classical opioid behaviors, such as hyperlocomotion or 
Straub tail (Table 3). A general behavioral action of  burrowing into the bedding was observed that is 
not associated with classical opioids, and the animals were clearly atypical in their overall behavior, 
showing a general tunneling behavior. Administration of  naloxone failed to counteract these behav-
iors. Similar burrowing behaviors were seen in rats after s.c. administration of  0.3 and 1.0 mg/kg.
Discussion
The major findings of  these studies are that both W-18 and W-15 are devoid of  significant opioid recep-
tor activity. Although W-18 and W-15 were described in the initial patent report as having potent analgesic 
activity in the phenylquinone-induced writhing assay, it should be noted that the test used cannot definitive-
ly identify the molecular target for the presumed “analgesic activity.” The nociceptive stimulus is relatively 
weak, with opioids active at doses far below those needed in thermal assays. Thus, as originally reported (2), 
Table 2. Binding affinities of W-15 and W-18 for targets with >50% inhibition in initial screen
Receptor Ki (pKi ± SEM, n)
W-15 W-18
5-HT2A 109 nM (6.96 ± 0.05, 3) 1,751 nM ( 5.76 ± 0.20, 3)
5-HT2B 380 nM (6.42 ± 0.11, 3) 2,171 nM (5.66 ± 0.19, 3)
5-HT2C 52 nM (6.91 ± 0.07, 3) 878 nM (6.06 ± 0.05, 3)
5-HT6 123 nM (6.91 ± 0.09, 3) 1,008 nM (6.00 ± 0.05, 3)
BZP 933 nM (6.03 ± 0.06, 3 ) 1,023 nM (5.99 ± 0.55, 3)
PBR 70 nM (7.16 ± 0.27, 4) 77 nM (7.11 ± 0.24, 4)
Α1 3,846 nM (5.42 ± 0.05, 2) 5,129 nM (5.29 ± 0.07, 2)
α2A 2,818 nM (5.55 ± 0.23, 4) 2,138 nM (5.67 ± 0.20, 4)
CB2 8,511 nM (5.07 ± 0.06, 3) 7,470 nM (5.13 ± 0.08, 3)
V1a 3,575 nM (5.45 ± 0.12, 3) 3,311 nM (5.48 ± 0.19, 3)
hERG 2,042 nM (5.69 ± 0.09, 3) 1,806 nM (5.74 ± 0.07, 3)
pKi represents the -log of the Ki value
Figure 2. Effect of W-15 and W-18 on opioid receptor–mediated Gαi signaling. The Gi-mediated inhibition of cAMP production was determined as
previously described (9–11). Both W-15 and W-18 showed no agonist activity at DOR (A), KOR (B), MOR (C), and nociceptin (NOP) (D) receptors and 
no antagonist activity at DOR (E), KOR (F), or MOR (G) receptors. Normalized results represent mean ± SEM of 3 independent experiments, each 
performed in triplicate (0% activity for vehicle activity; 100% for reference activity), and were analyzed in Prism.
Figure 3. Effect of W-15 and W-18 on opioid receptor–mediated β-arrestin recruitment. G protein–independent arrestin recruitment was determined in 
the GPCR Tango assay, as outlined in the Methods. Both W-15 and W-18 were tested and showed no agonist activity at DOR (A), KOR (B), MOR (C), and 
NOP (D) receptors and no antagonist effect at DOR (E), KOR (F), or MOR (G) receptors. Normalized results represent mean ± SEM of 3 independent experi-
ments, each performed in triplicate (0% for vehicle activity, and 100% for reference activity), and were analyzed in Prism.
a large assortment of  pharmacological agents show activity in this assay, including cholinesterase inhibitors, 
antihistamines, and antidepressants (15). In our hands, W-18 revealed no antinociceptive activity in either the 
thermal radiant heat tail-flick assay or the writhing assay. Furthermore, the atypical behaviors observed with 
the drugs (i.e., tunneling) failed to be reversed by naloxone, indicating that opioid receptors are not involved.
It is conceivable that W-18 and W-15 are prodrugs that require metabolic transformation for their effects 
in humans, as has been seen for toxic pharmaceuticals, including fenfluramine (16) and methysergide (17). 
Even the prescribed analgesic codeine requires demethylation to generate morphine for activity in both recep-
tor-binding assays and in vivo. W-18 undergoes extensive metabolism in both human and mouse liver micro-
somes; however, these metabolites do not reveal any affinity for opioid receptors. Behaviorally, W-18 failed 
to elicit any naloxone-sensitive actions. In addition, we saw no inhibition of  murine opioid receptor–binding 
from the W-18 metabolite mixture. The hepatic microsomal incubations provide an assessment of  in vivo rel-
evant metabolites but may not be comprehensive with respect to conjugation reactions, such as glucuronida-
tion of  primary W-18 metabolites. Although further studies aimed at identifying the individual metabolite(s) 
and determining their pharmacological activities are needed, and may uncover mechanisms contributing to 
the abuse potential of  W-18, our studies strongly indicate that opioid systems are not involved.
In conclusion, comprehensive evaluation of  the potential in vitro molecular pharmacology of  W-18 
and W-15 revealed no consensus targets for interaction. Although apparently devoid of  opioid receptor 
activity, weak activity of  W-18 at the peripheral benzodiazepine receptor was found, and the drugs appear 
to exhibit toxicity in HEK cells with overnight incubation at concentrations higher than 1 μM. The litera-
ture has suggested that W-18 falls into the opioid class of  drugs, possibly providing a false sense of  security 
for those abusing the compound who may rely upon its reversibility by naloxone. Given the lack of  appar-
ent activity at human or mouse cloned opioid receptors for the parent compounds or the metabolites, the 
utility of  naloxone and other opioid antagonists in treating overdose in humans is unlikely to be successful. 
This needs to be understood by both first responders and those abusing the compound.
Figure 4. Allosteric activity of W-18 on agonist stimulated inhibition of cAMP accumulation at opioid receptors. The Gi-mediated inhibition of 
cAMP production was determined as previously described (9–11) and in Methods. W-18 failed to modify the effect of DADLE at DOR (A), dynorphin 
A at KOR (B), dermorphin at MOR (C), or nociceptin at NOP (D) receptors. Normalized results represent mean ± SEM of 3 independent experiments, 
each performed in triplicate (0% for vehicle activity and 100% for reference activity), and were analyzed in Prism.
Methods
Drugs. W-18 and W-15 were purchased from Cayman Chemicals and supplied as >98% pure. Independent 
LC-MS quality control revealed the compounds were both pure and authentic.
Mice. CD-1 mice (20–30 g) were obtained from Charles River Laboratories and maintained on normal chow.
Cell lines. HEK93T cells were obtained from ATCC (catalog CRL-3216), and HTLA cells were obtained 
from Richard Axel (Columbia University).
Radioligand-binding assays. Radioligand-binding studies were performed as previously described 
using cloned, human receptors (18). Comprehensive profiling was performed using the resources of  the 
National Institute of  Mental Health Psychoactive Drug Screening Program as described previously (18). 
Initial screens were performed at 10,000 nM in quadruplicate. For targets with inhibition >50%, we 
also carried out concentration-response binding assays to determine affinities (Ki). Follow-up assays on 
murine opioid receptors expressed in CHO cells were carried out as previously described (19).
Metabolism studies. Metabolism was assessed using both mouse liver microsomes and pooled human liver 
microsomes incubated with NADPH (1 mM). Heat-inactivated microsomes and incubations without NADPH 
were used as controls. At various time points, 2 times the volume of acetonitrile was added to stop the incuba-
tion and precipitate the protein so the sample could be analyzed by mass spectrometry. Samples were analyzed 
using multiple methods on a Sciex 6500, operating in multiple reaction monitoring mode using predicted mass 
transitions, using precursor ion and product ion scans. Samples were further analyzed on a Thermo Scientific Q 
Exactive high-resolution mass spectrometer using full-scan mode operating at 70,000 resolution. Samples were 
also evaluated by HPLC using UV detection. HPLC-UV samples were processed by solid-phase extraction, 
dried using a vacuum centrifuge and reconstituted in a minimal volume of mobile phase.
In addition, a W-18 mixed-metabolite sample was prepared by incubating 40 μl of  a 20 mM W-18 
DMSO stock with 5 ml of  1 mg/ml human liver microsomes or mouse liver microsomes and 1 mM 
Figure 5. Allosteric activity of W-18 on agonist stimulated β-arrestin recruitment at opioid receptors. The arrestin recruitment activity was determined 
in the GPCR Tango assays, as outlined in the Methods. W-18 failed to modify the effect of DADLE at DOR (A), dynorphin A at KOR (B), dermorphin at MOR 
(C), or nociceptin at NOP (D) receptors. Normalized results represent mean ± SEM of 3 independent experiments, each performed in triplicate (0% activity 
for vehicle and 100% for reference activity), and were analyzed in Prism.
NADPH for 90 minutes. Metabolites were isolated using solid-phase extraction and dried using a speed 
vacuum. The mixed-metabolite sample was resolubilized, and the pooled metabolites were examined 
in opioid receptor–binding assays using the murine receptors expressed in CHO cells at concentrations 
corresponding to an initial concentration of  W-18 an initial concentration of  W-18 of  1 μM.
Figure 6. Agonist activities and antagonist effects of W-15 and W-18 at 5-HT2A, 5-HT2B, and 5-HT2C receptors. Gq-mediated calcium mobilization activity was 
determined using HEK293 cells stably expressing corresponding 5-HT2 subtypes on FLIPR
TETRA. Normalized results (relative fluorescence unit in fold of basal, basal 
was set as 0% and 5-HT Emax was set as 100%) represented mean values ± SEM from 2 independent assays, each performed in quadruplicate, and were analyzed 
in Prism. In antagonist activity assays, the reference agonist (5-HT) was used at a final concentration of 10 nM and was set as 0% inhibition and basal was set as 
100% inhibition. Panels A–C represent dose-response curves to 5-HT, W-15 and W-18 at 5-HT2A (A), 5-HT2B (B), or 5-HT2C (C) receptors. Panels D–F shows the 
antagonist activity of W-15 and W-18 at 5-HT2A (D), 5-HT2B (E), or 5-HT2C (F) receptors.
Figure 7. Concentration-dependent effect of W-15 
on 5-HT activity at 5-HT2A, 5-HT2B, and 5-HT2C 
receptors. 5-HT–mediated calcium mobilization was 
determined in the absence and presence of increas-
ing concentrations of W-15 using HEK293 cells stably 
expressing corresponding 5-HT2 subtypes on FLIPR-
TETRA. Normalized results (relative fluorescence unit 
in fold of basal, basal was set as 0%, and 5-HT Emax 
in the absence of W-15 was set as 100%) represent-
ed mean values ± SEM from 3 independent assays, 
each performed in triplicate, and were analyzed in 
Prism. Schild plot analysis (D) indicated W-15 is a 
competitive antagonist against 5-HT. The average 
pA2 values are 7.20 (5-HT2A), 5.38 (5-HT2B), and 
6.88 (5-HT2C). Panels A–C represent oncentration 
response curves for W-15 with increasing concentra-
tions of 5-HT at 5-HT2A (A), 5-HT2B (B), or 5-HT2C 
(C) receptors. 
Opioid receptor functional assays. Assays for agonist and antagonist activity at cloned opioid receptors 
were performed as previously described using cloned, human κ (9, 10), μ (11), δ, and nociceptin opioid 
receptors (12, 13). Assays for evaluating the allosteric modulation of  opioid receptors were performed 
using graded concentrations of  potential allosteric modulators in the absence and presence of  increasing 
concentrations of  the orthosteric ligand in a manner similar to a manner we recently described (20).
Profiling of  W-18 and W-15 against the druggable GPCR-ome. These studies were performed using our 
recently described PRESTO-Tango resource (14), which allows for the unbiased interrogation of  drugs 
against the entire, druggable GPCR-ome.
Analgesic studies. Antinociception was assessed using the writhing assay (15) and the radiant heat tail-
flick assay (21). The writhing assay assesses the response to an i.p. irritant, either acetic acid or phenylqui-
none, which yield similar responses. It is a weak stimulus, with activity shown by a wide range of  drugs as 
inactive in thermal assays, such as tail-flick and hot plate. In brief, groups of  mice received 1% acetic acid 
(10 μl/g, i.p.) 15 minutes after receiving the test drug, and writhes were counted from 5–15 minutes after 
Figure 8. W-15 and W-18 have no agonist activity at A1, α2A, 5-HT6, CB1, or CB2 receptors. Agonist activity (arrestin recruitment) was determined in GPCR 
Tango assays, as outlined in the Methods. Normalized results (basal was set as 0% and reference Emax was set as 100%) represented mean ± SEM from 
minimum of n assays (n = 2 for A and B, n = 3 for C–E), each performed in triplicate, and were analyzed in Prism. Panels A–E represent a dose response 
curve for A1-adenosine (A), a2-adrenergic (B), 5-HT6 receptors (C), CB1 receptors (D), or CB2 receptors (E).
acetic acid injection The radiant heat tail-flick assay involves placing the tail under a radiant heat source 
and determining the latency, defined as the time the mouse permits its tail to remain within the light beam. 
After establishing baseline latencies for each mouse, they receive the test drug and were tested again. A 
maximal exposure of  10 seconds was used to minimize any tissue damage. Results are provided as per-
centage maximal effects (%MPE), defined as (test latency – baseline latency)/(10 – baseline latency) × 100.
Predictive pharmacology. We used the similarity ensemble approach (22–24), essentially as previously 
described (22, 23, 25), to predict potential molecular targets for W-18 and W-15.
Data integrity and reproducibility. All dose-response assays were performed several times and repli-
cated independently, while the GPCR-ome analysis was performed twice in quadruplicate at different 
concentrations.
Statistics. For the behavioral assays, ANOVA and the 2-tailed Student’s t test were used with signifi-
cance predetermined to be at the 0.05 level, thus P < 0.05 was considered to be significant.
Study approval. All animal studies were approved by the Institutional Animal Care and Use Committee 
of  Memorial Sloan-Kettering Cancer Center and were conducted in strict accordance with the National 
Institutes of  Health Guide for the Care and Use of  Laboratory Animals (National Academies Press, 2011) in 
Figure 9. GPCR-ome screening with W-18 and W-15. GPCR-ome screening was conducted according to the PRESTO-Tango assays, as outlined in the Meth-
ods. W-15 and W-18 were screened at a final concentration of 1 μM, in quadruplicate for both sample and basal, and results are presented in fold of basal. 
Dopamine (D2) receptor with 100 nM quinpirole served as an assay control. A represents GPCRome screen of W-18. B represents GPCRome screen of W-15.
facilities accredited by the American Association for the Accreditation of  Laboratory Animal Care.
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